CAR-NK Cell Therapy for Relapsed Thymoma or Thymic Carcinoma
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new type of immune cell therapy called CAR-NK cells, which are designed to fight thymoma or thymic carcinoma (cancers of the thymus gland) that has come back or stopped responding to prior treatments. The goal is to see if these engineered cells can shrink tumors and help patients live longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–75 years old
- Biopsy-confirmed B2 thymoma or thymic carcinoma that cannot be surgically removed, has spread, or has returned after prior treatment
- At least one prior systemic cancer treatment (chemotherapy or similar)
- Tumor cells must express at least one of three markers (CD30, CD5, or mesothelin) on central lab testing
- Good overall health (ECOG performance status 0–1) and adequate organ function (blood counts, liver, and kidney)
- Willingness to use effective birth control if of childbearing age and able to sign informed consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether specially engineered NK cells can find and attack your type of cancer. It is for people with advanced solid tumors that haven't responded to standard treatments.
This trial tests a new treatment using engineered immune cells (CAR-NK cells) that target two markers found on glioblastoma tumors. The treatment is given directly into the brain to fight tumors that have come back after standard therapy.
This trial tests a new type of immune cell therapy (CAR-NK cells) that targets specific proteins on breast cancer cells. It's for people with advanced HER2-positive or triple-negative breast cancer who have tried other treatments or can't take them.
This trial tests a new cell therapy that uses your own immune cells to attack cancer. It's for people with small cell lung cancer that has come back or not responded to standard treatments.
This trial tests a new type of immune cell therapy called CAR-NK cells to treat glioblastoma or high-grade glioma that has come back or gotten worse after standard treatment. The cells are engineered to recognize and attack tumor cells in the brain.
This trial tests a new type of cell therapy using natural killer cells (immune cells) that are designed to recognize and attack head and neck cancer cells. The therapy targets two specific proteins (EGFR and HER2) found on cancer cells and is for patients whose cancer has returned or spread despite previous treatments.
Hear when a new Thymic Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.